Atherosclerosis induced by arsenic in drinking water in rats through altering lipid metabolism

Toxicology and Applied Pharmacology

Volumn 256, Issue 2, 2011, Pages 146-153

  Cheng, Tain Junn ^a,b,c   Chuu, Jiunn Jye ^d   Chang, Chia Yu ^b,d   Tsai, Wan Chen ^d   Chen, Kuan Jung ^d   Guo, How Ran ^a,e,f  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^d SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Arsenic; Atherosclerosis; Cholesteryl ester transfer protein; Liver X receptor; Reverse cholesterol transport

Indexed keywords

ARSENIC; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTERYL ESTER TRANSFER PROTEIN 1; DRINKING WATER; HEAT SHOCK PROTEIN 70; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARSENIC POISONING; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL DIET; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; LIPID METABOLISM; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT;

ANIMALS; ARSENICALS; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; HSP70 HEAT-SHOCK PROTEINS; LIPID METABOLISM; LIPOPROTEINS, HDL; LIVER; MALE; ORPHAN NUCLEAR RECEPTORS; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TRIGLYCERIDES; WATER POLLUTANTS, CHEMICAL; WATER SUPPLY;

RATTUS;

EID: 80053133051     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.08.001     Document Type: Article

References (57)

1. (SPSS) Inc Version 17.0 2008, SPSS Inc, Chicago, IL.
2. Agency for Toxic Substances and Disease Registry Toxicological profile for arsenic. U.S. Department of Health and Human Service, Public Health Service 2007, Agency for Toxic Substances and Disease Registry, Atlanta, GA.
3. Aguilar M.V., Martinez-Para M.C., González M.J. Effects of arsenic (V)-chromium (III) interaction on plasma glucose and cholesterol levels in growing rats. Ann. Nutr. Metab. 1997, 41:189-195.
4. Amarenco P., Benavente O., Goldstein L.B., Callahan A., Sillesen H., Hennerici M.G., Gilbert S., Rudolph A.E., Simunovic L., Zivin J.A., Welch M.A. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke 2009, 40:1405-1409.
5. Balakumar P., Kaur J. Arsenic exposure and cardiovascular disorders: an overview. Cardiovasc. Toxicol. 2009, 9:169-176.
6. Barter P.J., Brewer H.B., Chapman M.J., Hennekens C.H., Rader D.J., Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003, 23:160-167.
7. Bobryshev Y.V., Lord R.S.A. Expression of heat shock protein-70 by dendritic cells in the arterial intima and its potential significance in atherogenesis. J. Vasc. Surg. 2002, 35:368-375.
8. Bocher V., Millatt L.J., Fruchart J.C., Staels B. Liver X receptors: new players in atherogenesis?. Curr. Opin. Lipidol. 2003, 14:137-143.
9. Casquero A.C., Berti J.A., Salerno A.G., Bighetti E.J., Cazita P.M., Ketelhuth D.F., Gidlund M., Oliveira H.C. Atherosclerosis is enhanced by testosterone deficiency and attenuated by CETP expression in transgenic mice. J. Lipid Res. 2006, 47:1526-1534.
10. Castelli W.P., Anderson K., Wilson P.W.F., Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992, 2:23-28.
11. Cazita P.M., Berti J.A., Aoki C., Gidlund M., Harada L.M., Nunes V.S., Quintao E.C., Oliveira H.C. Cholesteryl ester transfer protein expression attenuates atherosclerosis in ovariectomized mice. J. Lipid Res. 2003, 44:33-40.
12. Chen C.-J., Wu M.-M., Lee S.-S., Wang J.-D., Cheng S.-H., Wu H.-Y. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arterioscler. Thromb. Vasc. Biol. 1988, 8:452-460.
13. Chen Y., Parvez F., Gamble M., Islam T., Ahmed A., Argos M., Graziano J.H., Ahsan H. Arsenic exposure at low-to-moderate levels and skin lesions, arsenic metabolism, neurological functions, and biomarkers for respiratory and cardiovascular diseases: review of recent findings from the Health Effects of Arsenic Longitudinal Study (HEALS) in Bangladesh. Toxicol. Appl. Pharmacol. 2009, 239:184-192.
14. Cheng T.-J., Ke D.-S., Guo H.-R. The association between arsenic exposure from drinking water and cerebrovascular disease mortality in Taiwan. Water Res. 2010, 44:5770-5776.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel III) J.A.M.A. 2001, 285:2486-2497.
16. Ferreccio C., González C., Milosavjlevic V., Marshall G., Sancha A.M., Smith A.H. Lung cancer and arsenic concentrations in drinking water in Chile. Epidemiology 2000, 11:673-679.
17. Föger B., Chase M., Amar M.J., Vaisman B.L., Shamburek R.D., Paigen B., Fruchart-Najib J., Paiz J.A., Koch C.A., Hoyt R.F., Brewer H.B., Santamarina-Fojo S. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J. Biol. Chem. 1999, 274:36912-36920.
18. Ghayour-Mobarhan M., Lamb D.J., Tavallaie S., Ferns G.A.A. Relationship between plasma cholesterol, von Willebrand factor concentrations, extent of atherosclerosis and antibody titres to heat shock proteins-60, -65 and -70 in cholesterol-fed rabbits. Int. J. Exp. Pathol. 2007, 88:249-255.
19. Gordon D.J., Knoke J., Probstfield J.L., Superko H.R., Tyroler H.A. High-density lipoprotein and heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation 1986, 74:1217-1225.
20. Groot P.H.E., Pearce N.J., Yates J.W., Stocker C., Sauermelch C., Doe C.P., Willette R.N., Olzinski A., Peters T., d'Epagnier D., Morasco K.O., Krawiec J.A., Webb C.L., Aravindhan K., Jucker B., Burgert M., Ma C., Marino J.P., Collins J.L., Macphee C.H., Thompson S.K., Jaye M. Synthetic LXR agonists increase LDL in CETP species. J. Lipid Res. 2005, 46:2182-2191.
21. Guo H.-R. Arsenic level in drinking water and mortality of lung cancer (Taiwan). Cancer Cause Control 2004, 15:171-177.
22. Guo H.-R., Chiang H.-S., Hu H., Lipsitz S.R., Monson R.R. Arsenic in drinking water and incidence of urinary cancer. Epidemiology 1997, 8:545-550.
23. Guo H.-R., Lipsitz S.R., Hu H., Monson R.R. Using ecological data to estimate a regression model for individual data: the association between arsenic in drinking water and incidence of skin cancer. Environ. Res. 1998, 79:82-93.
24. Harder C., Lau P., Meng A., Whitman S.C., McPherson R. Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice. Arterioscler. Thromb. Vasc. Biol. 2007, 27:858-864.
25. Hildebrand R.B., Lammers B., Meurs I., Korporaal S.J.A., Haan W.D., Zhao Y., Kruijt J.K., Praticò D., Schimmel A.W.M., Holleboom A.G., Hoekstra M., Kuivenhoven J.A., Berkel T.J.C.V., Rensen P.C.N., Eck M.V. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1439-1445.
26. Hirano K.-I., Yamashita S., Matsuzawa Y. Pros and cons of inhibiting cholesteryl ester transfer protein. Curr. Opin. Lipidol. 2000, 11:589-596.
27. Hopenhayn-Rich C., Biggs M.L., Fuchs A., Bergoglio R., Tello E.E., Nicolli H., Smith A.H. Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 1996, 7:117-124.
28. Hsieh Y.-C., Hsieh F.-I., Lien L.-M., Chou Y.-L., Chiou H.-Y., Chen C.-J. Risk of carotid atherosclerosis associated with genetic polymorphisms of apolipoprotein E and inflammatory genes among arsenic exposed residents in Taiwan. Toxicol. Appl. Pharmacol. 2008, 227:1-7.
29. Jin Y., Liang C., He G., Cao J. Study on distribution of endemic arsenism in China. J. Hygiene Res. 2003, 32:519-540.
30. Kimura H., Miyazaki R., Suzuki S., Gejyo F., Yoshida H. Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. Am. J. Kidney Dis. 2001, 38:70-76.
31. Lewis D.R., Southwick J.W., Ouellet-Hellstrom R., Rench J., Calderon R.L. Drinking water arsenic in Utah: A cohort mortality study. Environ. Health Perspect. 1999, 107:359-365.
32. Li W.-F., Sun C.-W., Cheng T.-J., Chang K.-H., Chen C.-J., Wang S.-L. Risk of carotid atherosclerosis is associated with low serum paraoxonase (PON1) activity among arsenic exposed residents in Southwestern Taiwan. Toxicol. Appl. Pharmacol. 2009, 236:246-253.
33. MacLean P.S., Bower J.F., Vadlamudi S., Osborne J.N., Bradfield J.F., Burden H.W., Bensch W.H., Kauffman R.F., Barakat H.A. Cholesteryl ester transfer protein expression prevents diet-induced atherosclerotic lesions in male db/db mice. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1412-1415.
34. Markowski V.P., Currie D., Reeve E.A., Thompson D., Wise J.P. Tissue-specific and dose-related accumulation of arsenic in mouse offspring following maternal consumption of arsenic-contaminated water. Basic Clin. Pharmacol. Toxicol. 2011, 108:326-332.
35. Masson D., Staels B., Gautier T., Desrumaux C., Athias A., Le Guern N., Schneider M., Zak Z., Dumont L., Deckert V., Tall A., Jiang X.C., Lagrost L. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. J. Lipid Res. 2004, 45:543-550.
36. Meliker J.R., Wahl R.L., Cameron L.L., Nriagu J.O. Arsenic in drinking water and cerebrovascular disease, diabetes mellitus, and kidney disease in Michigan: a standardized mortality ratio analysis. Environ. Health 2007, 6:4-15.
37. Mittal M., Flora S.J. Effects of individual and combined exposure to sodium arsenite and sodium fluoride on tissue oxidative stress, arsenic and fluoride levels in male mice. Chem. Biol. Interact. 2009, 162:128-139.
38. Mukherjee S. Atherosclerosis: cell biology and lipoproteins: C-reactive protein is a biomarker of atherosclerosis and mediator of plaque formation. Curr. Opin. Lipidol. 2004, 15:623-625.
39. Nissen S.E., Tsunoda T., Tuzcu E.M., Schoenhagen P., Cooper C.J., Yasin M., Eaton G.M., Lauer M.A., Sheldon W.S., Grines C.L., Halpern S., Crowe T., Blankenship J.C., Kerensky R. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. J.A.M.A. 2003, 290:2292-2300.
40. Okamoto H., Yonemori F., Wakitani K., Minowa T., Maeda K., Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000, 406:203-207.
41. Padovani A.M.S., Molina M.F., Mann K.K. Inhibition of liver X receptor/retinoid X receptor mediated transcription contributes to the proatherogenic effects of arsenic in macrophages in vitro. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1228-1236.
42. Paffen E., deMaat M.P.M. C-reactive protein in atherosclerosis: a causal factor?. Cardiovasc. Res. 2006, 71:30-39.
43. Peng D., Hiipakka R.A., Xie J.T., Reardon C.A., Getz G.S., Liao S. Differential effects of activation of liver X receptor on plasma lipid homeostasis in wild-type and lipoprotein clearance-deficient mice. Atherosclerosis 2010, 208:126-133.
44. Rencher A.C., Carter M.W., McKee D.W. A retrospective epidemiological study of mortality at a large western copper smelter. J. Occup. Med. 1977, 19:754-758.
45. Repa J.J., Mangelsdorf D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nature Med. 2002, 8:1243-1248.
46. Ritsch A., Scharnagl H., Eller P., Tancevski I., Duwensee K., Demetz E., Sandhofer A., Boehm B.O., Winkelmann B.R., Patsch J.R., März W. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography. The Ludwigshafen risk and cardiovascular health study. Circulation 2010, 121:366-374.
47. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
48. Simeonova P.P., Hulderman T., Harki D., Luster M.I. Arsenic exposure accelerates atherogenesis in apolipoprotein E-/- mice. Environ. Health Perspect. 2003, 111:1744-1748.
49. Smith A.H., Lingas E.O., Rahman M. Contamination of drinking-water by arsenic Bangladesh: a public health emergency. Bull. W.H.O. 2000, 78:1093-1103.
50. Tchoua U., D'Souza W., Mukhamedova N., Blum D., Niesor E., Mizrahi J., Maugeais C., Sviridov D. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc. Res. 2008, 77:732-739.
51. Tsou T.-C., Yeh S.C., Tsai E.-M., Tsai F.-Y., Chao H.-R., Chang L.W. Arsenite enhances tumor necrosis factor-α-induced expression of vascular cell adhesion molecule-1. Toxicol. Appl. Pharmacol. 2005, 209:10-18.
52. Varsányi I., Fodré Z., Bartha A. Arsenic in drinking water and mortality in the southern Great Plain, Hungary. Environ. Geochem. Health 1991, 13:14-22.
53. Wang C.H., Jeng J.S., Yip P.K., Chen C.L., Hsu L.I., Hsueh Y.M., Chiou H.-Y., Wu M.-M., Chen C.-J. Biological gradient between long-term arsenic exposure and carotid atherosclerosis. Circulation 2002, 105:1804-1809.
54. Wang C.-H., Hsiao C.K., Chen C.-L., Hsu L.-I., Chiou H.-Y., Chen S.-Y., Hsueh Y.-M., Wu M.-M., Chen C.-J. A review of the epidemiologic literature on the role of environmental arsenic exposure and cardiovascular diseases. Toxicol. Appl. Pharmacol. 2007, 222:315-326.
55. Yang H.-T., Chou H.-J., Han B.-C., Huang S.-Y. Lifelong inorganic arsenic compounds consumption affected blood pressure in rats. Food Chem. Toxicol. 2007, 45:2479-2487.
56. Yu G., Sun D., Zheng Y. Health effects of exposure to natural arsenic in groundwater and coal in China: an overview of occurrence. Environ. Health Perspect. 2007, 115:636-642.
57. Zhang Z., Yamashita S., Hirano K., Nakagawa-Toyama Y., Matsuyama A., Nishida M., Sakai N., Fukasawa M., Arai H., Miyagawa J., Matsuzawa Y. Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport. Atherosclerosis. 2001, 159:67-75.